PFO
KROS icon

Pathstone Family Office’s Keros Therapeutics KROS Stock Holding History

Pathstone Family Office’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,267
Closed -$47K – 906
2020
Q2 		$47K Buy
+1,267
New +$39K 0.01% 326

Other funds holding KROS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Pathstone Family Office's KROS Position: Q3 2020 in Review

Pathstone Family Office sold out of Keros Therapeutics (KROS) in Q3 2020, closing a stake of 1,267 shares — an estimated $47K sold.

Pathstone Family Office first reported a position in KROS in Q2 2020 and held it in 1 quarter. The position peaked at $47K in Q2 2020. 49 funds tracked by Wall St. Rank hold KROS as of Q3 2020.

  • Pathstone Family Office reported no remaining Keros Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 1,267 Keros Therapeutics shares in Q3 2020, an estimated $47K.
  • Pathstone Family Office first reported a position in Keros Therapeutics in Q2 2020 and held it in 1 quarter.
  • Pathstone Family Office's Keros Therapeutics position peaked at $47K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.